Fintel reports that on September 12, 2023, Lake Street maintained coverage of Bioceres Crop Solutions (NASDAQ:BIOX) with a Buy recommendation.
Analyst Price Forecast Suggests 120.56% Upside
As of August 31, 2023, the average one-year price target for Bioceres Crop Solutions is 25.81. The forecasts range from a low of 15.15 to a high of $32.55. The average price target represents an increase of 120.56% from its latest reported closing price of 11.70.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Bioceres Crop Solutions is 543MM, an increase of 30.58%. The projected annual non-GAAP EPS is 0.85.
What is the Fund Sentiment?
There are 65 funds or institutions reporting positions in Bioceres Crop Solutions. This is an increase of 1 owner(s) or 1.56% in the last quarter. Average portfolio weight of all funds dedicated to BIOX is 0.32%, a decrease of 12.89%. Total shares owned by institutions decreased in the last three months by 3.72% to 8,813K shares. 
The put/call ratio of BIOX is 0.47, indicating a bullish outlook.
What are Other Shareholders Doing?
Solel Partners holds 4,579K shares representing 7.29% ownership of the company. No change in the last quarter.
Ardsley Advisory Partners holds 1,853K shares representing 2.95% ownership of the company. In it's prior filing, the firm reported owning 1,943K shares, representing a decrease of 4.85%. The firm decreased its portfolio allocation in BIOX by 15.57% over the last quarter.
Arisaig Partners (Asia) Pte holds 266K shares representing 0.42% ownership of the company. No change in the last quarter.
Allianz Asset Management holds 232K shares representing 0.37% ownership of the company. In it's prior filing, the firm reported owning 148K shares, representing an increase of 35.92%. The firm decreased its portfolio allocation in BIOX by 99.65% over the last quarter.
Wellington Management Group Llp holds 230K shares representing 0.37% ownership of the company. In it's prior filing, the firm reported owning 233K shares, representing a decrease of 0.98%. The firm increased its portfolio allocation in BIOX by 8.75% over the last quarter.
Bioceres Crop Solutions Background Information
(This description is provided by the company.)
Bioceres Crop Solutions Corp. is a fully integrated provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. To do this, Bioceres' solutions create economic incentives for farmers and other stakeholders to adopt environmentally friendlier production practices. The Company has a unique biotech platform with high-impact, patented technologies for seeds and microbial ag-inputs, as well as next generation crop nutrition and protection solutions. Through its HB4® program, the Company is bringing digital solutions to support growers' decisions and provide end-to-end traceability for production outputs.
Additional reading:
- BIOCERES CROP SOLUTIONS FOURTH QUARTER 2023 1 Bioceres Crop Solutions Reports Fiscal Fourth Quarter and Full Year 2023 Financial and Operational Results FY23 revenues up 25% and Adjusted EBITDA at $81.1 million ROSARIO, Argentina – September 11, 2023
- Corteva Agriscience and Bioceres Crop Solutions to Advance Availability of Biologicals in Europe The Companies Signed an Exclusive Agreement on Distribution of Innovative Bioinsecticide
- BIOCERES CROP SOLUTIONS CORP. Unaudited interim condensed consolidated financial statements as of March 31, 2023 and June 30, 2022, and for the three and nine-month periods ended March 31, 2023, and 2022.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
